BioCentury
ARTICLE | Management Tracks

Orphazyme hires Amgen’s Bourdon as CEO; plus Tsang joins Ropes & Gray, and updates from Karolinska, Kadmon, Immunicum, InnoCare, Abivax    

March 2, 2021 12:30 AM UTC

Amgen Inc. (NASDAQ:AMGN) oncology veteran Christophe Bourdon will become CEO of  Orphazyme A/S (CSE:ORPHA; NASDAQ:ORPH) April 1, pending confirmation by the Danish orphan neurodegenerative disease company’s board. At Amgen, Bourdon led commercialization planning and execution for multiple drugs as SVP and general manager of the U.S. oncology business. Before Amgen, he was SVP of Europe, Middle East, Africa and Canada at Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) while the company launched two ultra-orphan drugs. Bourdon succeeds Kim Stratton, who resigned in December.

Ropes & Gray hired Lincoln Tsang as partner to lead its European life sciences regulatory practice. He previously led the life sciences regulatory practice at Arnold & Porter...